Quantitative Genomic RNA from Severe acute respiratory syndrome-related coronavirus 2 strain USA/GA-EHC-2811C/2021 (Omicron variant)
VR-3347D ™
Download Genome Learn about the ATCC Genome PortalVR-3347D ™
Download Genome Learn about the ATCC Genome PortalATCC determines the biosafety level of a material based on our risk assessment as guided by the current edition of Biosafety in Microbiological and Biomedical Laboratories (BMBL), U.S. Department of Health and Human Services. It is your responsibility to understand the hazards associated with the material per your organization’s policies and procedures as well as any other applicable regulations as enforced by your local or national agencies.
This isolate is lineage BA.1 (Pango v.3.1.19 2022-01-20), Omicron (BA.1-like) (Scorpio), and GISIAD clade GRA using the Phylogenetic Assignment of Named Global Outbreak lineages (PANGO) tool. Due to the dynamic nature of lineage determination using PANGO, discrepancies may exist between vial labels and the current lineage assignment. Previous iterations of PANGO identified this isolate as lineage B.1.1.529.
The complete genome of the clinical isolate of SARS-CoV-2, USA/GA-EHC-2811C/2021 has been sequenced (GISAID: EPI_ISL_7171744). The following mutations are present in the clinical isolate: Spike A67V, Spike D614G, Spike D796Y, Spike E484A, Spike G142D, Spike G339D, Spike G446S, Spike G496S, Spike H69del, Spike H655Y, Spike ins214EPE, Spike K417N, Spike L212I, Spike L981F, Spike N211del, Spike N440K, Spike N501Y, Spike N679K, Spike N764K, Spike N856K, Spike N969K, Spike P681H, Spike Q493R, Spike Q498R, Spike Q954H, Spike S371L, Spike S373P, Spike S375F, Spike S477N, Spike T95I, Spike T478K, Spike T547K, Spike V70del, Spike V143del, Spike Y144del, Spike Y145del, Spike Y505H, E T9I, M A63T, M D3G, M Q19E, N E31del, N G204R, N P13L, N R32del, N R203K, N S33del, NSP3 A1892T, NSP3 K38R, NSP3 L1266I, NSP3 S1265del, NSP4 T492I, NSP5 P132H, NSP6 G107del, NSP6 I189V, NSP6 L105del, NSP6 S106del, NSP12 P323L, NSP14 I42V. It was labelled as variant of concern (VOC) Omicron by the World Health Organization (WHO).
Genomic RNA from SARS-CoV-2 must be handled at BSL-2 containment level.
Acknowledgment for publications should read "The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: Genomic RNA from SARS-Related Coronavirus 2, Isolate hCoV-19/USA/GA-EHC-2811C/2021 (Lineage B.1.1.529; Omicron Variant), NR-56494."
The product is provided 'AS IS' and the viability of ATCC® products is warranted for 30 days from the date of shipment, provided that the customer has stored and handled the product according to the information included on the product information sheet, website, and Certificate of Analysis. For living cultures, ATCC lists the media formulation and reagents that have been found to be effective for the product. While other unspecified media and reagents may also produce satisfactory results, a change in the ATCC and/or depositor-recommended protocols may affect the recovery, growth, and/or function of the product. If an alternative medium formulation or reagent is used, the ATCC warranty for viability is no longer valid. Except as expressly set forth herein, no other warranties of any kind are provided, express or implied, including, but not limited to, any implied warranties of merchantability, fitness for a particular purpose, manufacture according to cGMP standards, typicality, safety, accuracy, and/or noninfringement.
This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. Any proposed commercial use is prohibited without a license from ATCC.
While ATCC uses reasonable efforts to include accurate and up-to-date information on this product sheet, ATCC makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. ATCC does not warrant that such information has been confirmed to be accurate or complete and the customer bears the sole responsibility of confirming the accuracy and completeness of any such information.
This product is sent on the condition that the customer is responsible for and assumes all risk and responsibility in connection with the receipt, handling, storage, disposal, and use of the ATCC product including without limitation taking all appropriate safety and handling precautions to minimize health or environmental risk. As a condition of receiving the material, the customer agrees that any activity undertaken with the ATCC product and any progeny or modifications will be conducted in compliance with all applicable laws, regulations, and guidelines. This product is provided 'AS IS' with no representations or warranties whatsoever except as expressly set forth herein and in no event shall ATCC, its parents, subsidiaries, directors, officers, agents, employees, assigns, successors, and affiliates be liable for indirect, special, incidental, or consequential damages of any kind in connection with or arising out of the customer's use of the product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, ATCC is not liable for damages arising from the misidentification or misrepresentation of such materials.
Please see the material transfer agreement (MTA) for further details regarding the use of this product. The MTA is available at www.atcc.org.
If shipping to the U.S. state of Hawaii, you must provide either an import permit or documentation stating that an import permit is not required. We cannot ship this item until we receive this documentation. Contact the Hawaii Department of Agriculture (HDOA), Plant Industry Division, Plant Quarantine Branch to determine if an import permit is required.
Rambaut A, et al. A Dynamic Nomenclature Proposal for SARS-CoV-2 Lineages to Assist Genomic Epidemiology. Nat Microbiol 5: 1403-1407, 2020. PubMed: 32669681
Mercatelli D and Giorgi FM. Geographic and Genomic Distribution of SARS-CoV-2 Mutations. Front Microbiol: doi.org/10.3389/fmicb.2020.01800, 2020. PubMed: 32793182
Gralinski LE and Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses 12: 135, 2020. PubMed: 31991541